Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year
Date:2/24/2011

60;During 2009, within Generics, Mylan recognized $28.5 million of incremental other revenue resulting from the cancellation of product development agreements for which the revenue had been previously deferred.  There was no such revenue recognized during the current year.  

A tabular summary of the Company's revenues for the years ended December 31, 2010, and 2009, is included at the end of this release.

Generics third party net sales were $4.98 billion in 2010, compared to $4.61 billion in prior year.

Third party net sales from North America were $2.36 billion in 2010, compared to $2.09 billion for the prior year, representing an increase of $265.0 million, or 12.6%. The increase was driven by increased volume, new product launches and incremental revenue from the Bioniche Pharma acquisition, partially offset by unfavorable pricing on certain existing products, including divalproex sodium extended-release (divalproex ER) tablets, the generic version of Abbott Laboratories' Depakote® ER, for which Mylan had exclusivity for a portion of 2009.

New products launched in the US and Canada contributed sales of $158.6 million, over half of which consisted of valacyclovir hydrochloride tablets, the generic version of GlaxoSmithKline's Valtrex®, and minocycline hydrochloride extended release tablets, the generic version of Medicis Pharmaceutical Corporation's Solodyn® ER.  The Company's ability to continue to be a stable and reliable source of supply to the market resulted in the favorable volume on its existing product base.

Third party net sales from EMEA were $1.55 billion for 2010, compared to $1.64 billion for the prior year, a decrease of $90.8 million, or 5.5%. However, translating current year third party net revenues from EMEA at prior year exchange rates would result in a decrease excluding the effect of foreign currency translations of approximately $24 million, or 1%.  This decrease was m
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
2. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
3. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
4. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
5. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
6. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
7. Mylan Confirms Four First-to-File Challenges
8. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
9. Mylans Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
10. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
11. Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... July 7, 2015 Summary ... Therapy Market Analysis" report is an essential source ... field. Using detailed company data, deal analysis, corporate ... in-depth analysis of the current and future growth ... discusses the key factors shaping and driving the ...
(Date:7/7/2015)... July 7, 2015 Genes in Space, ... 7-12, is landing at New England Biolabs® (NEB®) ... day of scientific exploration and celebration, on Thursday, ... partnership between Boeing®, The Center for Advancement of ... asked students to design an experiment to solve ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... growing demand for biologic are some of the factors driving the pharmaceutical contract ... drug manufacturers, as well as contract manufacturing organizations (CMOs), are driving market growth. ...
(Date:7/7/2015)... Ottawa, ON (PRWEB) , ... July 07, 2015 ... ... kits and end-to-end services and a subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR) ... completion of a comprehensive technical validation and self declaration under the European Directive ...
Breaking Biology Technology:PharmaSphere: Emerging Biotechnologies - Gene Therapy Market Analysis 2Genes in Space finalists attend laboratory workshop and celebration at New England Biolabs' headquarters 2More Drug Companies Increasing Outsourcing Budgets; CMO Partners Spring Up as Market Thrives, According to BCC Research 2More Drug Companies Increasing Outsourcing Budgets; CMO Partners Spring Up as Market Thrives, According to BCC Research 3DNA Genotek Inc. Receives CE-IVD Mark for its OMNIgene®•GUT Microbiome Collection Kit 2
... 4, 2010 Four world-renowned,stem cell experts have recently given their ... Blood Bank" which has,just been established in the US by CORD:USE. , ... Cryo-Save ... pleased with this positive development. "We expect that the merit of,private storage ...
... Chinese researchers have successfully built an electromagnetic absorbing device ... cylinder comprising 60 concentric rings of metamaterials, is capable ... an astrophysical black hole (which, in space, soaks up ... Thursday, 3 June, in New Journal of Physics ...
... June 3 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), ... the newly created position of President and Chief Operating Officer. Dr. ... responsibility for its operations and infrastructure, in particular the development and ... , , ...
Cached Biology Technology:Scientists Give the Go-Ahead for Private Storage of Stem Cells From Umbilical Cord Blood 2Scientists Give the Go-Ahead for Private Storage of Stem Cells From Umbilical Cord Blood 3Scientists create artificial mini 'black hole' 2YM BioSciences appoints Dr. Nick Glover as President and Chief Operating Officer 2YM BioSciences appoints Dr. Nick Glover as President and Chief Operating Officer 3YM BioSciences appoints Dr. Nick Glover as President and Chief Operating Officer 4YM BioSciences appoints Dr. Nick Glover as President and Chief Operating Officer 5
(Date:7/7/2015)... 2015 Research and ... of the "Capacitive Fingerprint Sensors Patent Landscape" ... this date, fingerprint sensing technology is the most ... are well developed. This patent landscape focuses on ... The domain of capacitive fingerprint sensors is closely ...
(Date:7/7/2015)... Calif. , July 7, 2015  Based ... market, Frost & Sullivan recognizes Credence ID, LLC ... Entrepreneurial Company of the Year Award. Credence ... to aid in its mission of offering enrollment ... populations globally. As Credence ID was formed by ...
(Date:7/7/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... commerce market announces a revised version of one of its first ... air on CNBC in New York , ... San Francisco metro areas.    ... ability to replace all the cards in your wallet and keep ...
Breaking Biology News(10 mins):Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... developed analytical technique, a team led by scientists at USC ... in the ocean. "This is another twist to what ... biological and earth sciences at the USC Dornsife College of ... about the vitamin-depleted zones that will appear in Proceedings ...
... Connecticut researcher and his team have discovered that a ... blooms sometimes called "red tide" is even deadlier than ... chains. Professor Hans Dam and his research group ... that the plankton species Alexandrium tamarense contains ...
... Center for Laser Applications at the University of ... technology that goes on a "seek and destroy" ... power of lasers to find, map and non-invasively ... professor of physics, and Jacqueline Johnson, associate professor ...
Cached Biology News:Scientists confirm existence of vitamin 'deserts' in the ocean 2UConn researchers discover that 'red tide' species is deadlier than first thought 2University of Tennessee Space Institute researchers develop laser technology to fight cancer 2
... a base medium for preparation of minimal and ... but does not contain amino acids. Both bulk ... pouch contains reagents to prepare 500 ml of ... of 10X YNB for S. cerevisiae media. Store ...
... Progesterone Receptor (PR) Competitor Assay Kits ... novel progesterone receptor binding compounds using ... utilizes a fusion of glutathione transferase ... human progesterone receptor [PR-LBD(GST)] and a ...
... Protein G bind specifically to Fc regions ... Protein G conjugates are commonly used as ... immunoglobulin subtypes from serum, hybridoma ascites fluids, ... These reagents are also commonly used to ...
... the first instrument engineered to match the ... by thousands of research centers worldwide. It ... which are ideally suited for high-speed temperature ... extremely high surface-area-to-volume ratio. ,By combining glass ...
Biology Products: